Session III: September 21, 2022
Increasing the Participation of African American Patients in Prostate Cancer Clinical Trials
African American (AA) men are poorly represented in prostate cancer clinical trials relative to their disease burden and proportional representation in the general population. There is an unquestioned need to increase the AA participation in prostate cancer clinical trials to ensure that trial results reflect how this population that is most impacted by prostate cancer, will respond to the diagnostic and therapeutic products being investigated. This session will examine issues contributing to the inadequate representation of AA patients in these trials, and approaches to increasing participation.
Prior Summit Images
Welcome and Opening Remarks: Mr. Thomas Farrington, President and Founder, PHEN Watch Video
Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN
Disparities in the Era of Precision Medicine
Won Kim, MD, Senior Medical Director in Clinical Oncology, Janssen Watch Video
Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions
Elisabeth Heath, MD, FACP, Professor of Oncology & Medicine, Karmanos Cancer Institute Watch Video
Panel Discussion: The session presenters will be joined on the panel by other leaders to discuss the prostate cancer disparity, clinical trials enrollment and solutions to increase participation of African American men in clinical trials. Watch Video
Lola A. Fashoyin-Aje, MD, MPH, Oncologist and Deputy Division Director, Food and Drug Administration (FDA)
Neil Fleshner, MD, MPH, FRCSC, Chair, Division of Urology, Professor, Department of Surgery, University of Toronto
Mr. Euvon Jones, PHEN Ambassador
Justin Lorentz, MS, Genetic Counselor, Odette Cancer Center, Sunny Brook Health Center
Linda Murakami, Director of Advocacy, Amgen Oncology
Yaw Nyame, MD, Assistant Professor and OCOE Program Lead, Department of Urology, Fred Hutch Cancer Center, University of Washington
Carmen White, Multicultural Participant Experience Lead, Pfizer Global Product Development Division
Closing Remarks: Mr. Thomas Farrington
SPONSORS
PHEN thanks its sponsors for their invaluable support of the 2022 Summit.
